newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - MINERVA NEUROSCIENCES INC

  • Financial Performance:

    • No specific financial metrics (revenue, earnings, cash flow, debt) were disclosed as the company is in clinical development and pre-commercialization.
    • Raised $200 million in financing in October of the prior year to support ongoing operations and future commercialization efforts.
    • Explicitly noted that the recent capital raise is insufficient to fully fund the commercialization infrastructure required post-approval.
  • Guidance and Future Outlook:

    • Phase 3a (Confirmatory) Readout: Expected in the second half of 2027 for Part A (12-week efficacy data).
    • Phase 3b (Safety/Relapse) Readout: Expected in the second half of 2028 for Part B (one-year safety and relapse comparison).
    • Long-term Goal: Establish Roliparidone as a monotherapy for stable schizophrenia patients with negative symptoms, shifting away from continuous antipsychotic use.
    • Commercialization: Actively preparing commercialization strategies, including patient/caregiver education and prescriber training, ahead of the 2027 data readout.
  • Business Segments and Product Lines:

    • Product: Roliparidone, a novel therapeutic targeting negative symptoms in schizophrenia.
    • Mechanism: Utilizes 5-HT2A serotonergic activity rather than dopaminergic D2 blockade to avoid worsening negative symptoms.
    • Study Design: Confirmatory trial includes Part A (efficacy vs. placebo) and Part B (safety/relapse vs. antipsychotics).
    • Patient Selection: Focusing on a specific subset of ~900,000 US patients with stable positive symptoms and impairing negative symptoms.
    • Patent Estate: Holds a composition of matter patent expiring in 2038 (plus pediatric extensions); includes a complex formulation/process patent (not standard formulation) and other families pending inclusion in the Orange Book.
  • Market and Competitive Landscape:

    • Market Size: Addresses ~900,000 target patients in the US out of a total schizophrenia population of ~3.2 million.
    • Competitive Gap: Current antipsychotics treat positive symptoms but often worsen negative symptoms; no existing approved therapy specifically targets negative symptoms in stable patients.
    • Clinical Differentiation: Roliparidone demonstrates a low relapse rate (10-15% over one year) compared to the 27-30% relapse rate typically seen with antipsychotics in meta-analyses.
    • Regulatory Path: FDA has aligned with the company's approach following a public meeting, validating the need for stable patient populations and long-term placebo-controlled studies.
  • Risks and Challenges:

    • Screening Complexity: High screen failure rates due to strict criteria requiring 6-month stability and specific negative symptom scores (e.g., PANSS-MARTAR >20).
    • Placebo Control: Managing high placebo responses and "nursing effects" in patients with negative symptoms (amotivation, lack of pleasure); mitigated by minimizing patient-site contact to caregiver-only interactions.
    • Regulatory Uncertainty: While FDA dialogue is constructive, the final determination on the black box warning and labeling remains with the agency.
    • Commercial Execution: Significant need for capital to build marketing, distribution, and educational infrastructure post-approval.
  • Management Commentary and Tone:

    • Tone: Highly confident and constructive; management emphasizes a "paradigm shift" in treating schizophrenia.
    • Expertise: CEO Remy Luthringer speaks from clinical background, validating the biological rationale for avoiding dopamine blockade.
    • Data Integrity: Highlights rigorous data quality, noting that strict inclusion criteria (e.g., rejecting patients with scores of 19 vs. 20) indicate high site performance and low variability.
    • Strategic Focus: Emphasizes accumulating evidence of functional improvement (PSP scores) rather than just symptom scores.
  • Analyst Questions and Answers:

    • Q: How does Roliparidone compare to antipsychotics regarding negative symptoms?
      • A: Antipsychotics do not help negative symptoms and often worsen them (secondary negative symptoms); Roliparidone aims to treat these specifically.
    • Q: How did the company control for placebo in Phase 3?
      • A: Used a single high dose (64mg) to maximize the treatment delta; implemented patient selection committees; reduced site variability via detailed scorer retraining; minimized "nursing effect" by limiting direct patient interaction.
    • Q: What are the relapse rates observed?
      • A: Roliparidone showed 10-15% relapse over one year vs. 27-30% for antipsychotics in historical data; Part B aims to show similar relapse rates between the two treatments to support monotherapy.
    • Q: Why is the primary endpoint set at 12 weeks if the study is longer?
      • A: Phase 3a is powered to show a statistically significant difference (1-2 point delta) on the PANSS-MARTAR at week 12; Phase 3b is purely for safety/descriptive relapse data.
  • Other Key Points:

    • Drug Name: The transcript mentions the drug as "Rhooperidone" and "Roliparidone"; standard pharmaceutical spelling is likely "Roliperidone" (clarification needed based on external knowledge, but transcript uses these variations).
    • Safety Profile: No black box warning anticipated for Roliparidone as it does not block post-synaptic D2 receptors, which is a primary driver of mortality in traditional antipsychotics.
    • Study Specifics: Dropout rates in previous studies were ~30%, but over half were due to personal/family reasons rather than drug toxicity.
    • Market Strategy: Management is preparing to educate the market on the concept of "treatment-free" maintenance for stable patients, contrasting with current standard of care.
Company
MINERVA NEUROSCIENCES INC
Keywords
MINERVA NEUROSCIENCES INC